Abstract 1598P
Background
The importance of Hospice & Palliative care for patients with terminal cancer is well established. Although hospice use is increasing, the use of hospice services is still suboptimal. Previous studies reported that surgeons tend to underuse palliative care (PC) consultation. This study aimed to investigate potential variations in referral patterns to the PC team and differences in end-of-life care among specialized physicians in patients with terminal cancer.
Methods
A single-institution retrospective observational study of consecutive PC consultations within a National Cancer Institute-designated cancer center in 2020-2021 was conducted. We categorized specialized physicians into medical oncologists (MO) and non-medical oncologists (NMO), which include hematologists, gastroenterologists, surgical and radiation oncologists.
Results
We analyzed 1710 patients, 1130 were referred from MO and 580 from NMO. Patients in the NMO group had lower levels of prognostic awareness (PA) regarding their terminal cancer status compared to those in MO. 44.7 % of patients in the MO group and 16.2 % of patients in the NMO group had accurate PA (p<0.01). The median survival from a day of PC consultation was 40.7 days for all, 47.3 days for the MO group, and 28 days for NMO group (p = 0.00). The survival time after planning Advance Directives was 100 days for all, significantly longer in the MO group (131.2 vs. 54.9 days, p=0.00). The median time from notification of discontinuation of active cancer treatment to PC consultation was 40 days. The interval to PC consultation was significantly longer in patients referred from the NMO group (92.6 days in the NMO group vs. 13.5 days in the MO group, p=0.00). The rate of discharge to specialized inpatient hospice facilities or home hospice was higher in the MO group. However, the discharge rate to acute-stage hospital, ICU was higher in the NMO group.
Conclusions
There was significant variation in referral patterns to the PC team according to a division of physicians. NMO patients had a lower level of prognostic awareness (PA) compared to MO patients. Late referrals to the PC team were observed in the NMO group. This suggests a need for increased education and training in palliative care for the NMO.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05